tiprankstipranks
Lixte Biotechnology Holdings (LIXT)
NASDAQ:LIXT

Lixte Biotechnology Holdings (LIXT) Price & Analysis

Compare
70 Followers

LIXT Stock Chart & Stats


---

Financials

Quarterly

Ownership Overview

4.98%0.82%6.65%87.35%
4.98%
Insiders
6.65% Other Institutional Investors
87.35% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

LIXT FAQ

What was Lixte Biotechnology Holdings’s price range in the past 12 months?
Lixte Biotechnology Holdings lowest stock price was $1.02 and its highest was $3.80 in the past 12 months.
    What is Lixte Biotechnology Holdings’s market cap?
    Lixte Biotechnology Holdings’s market cap is $3.25M.
      When is Lixte Biotechnology Holdings’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Lixte Biotechnology Holdings’s earnings last quarter?
      Lixte Biotechnology Holdings released its earnings results on Apr 27, 2018. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.06.
        Is Lixte Biotechnology Holdings overvalued?
        According to Wall Street analysts Lixte Biotechnology Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Lixte Biotechnology Holdings pay dividends?
          Lixte Biotechnology Holdings does not currently pay dividends.
          What is Lixte Biotechnology Holdings’s EPS estimate?
          Lixte Biotechnology Holdings’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Lixte Biotechnology Holdings have?
          Lixte Biotechnology Holdings has 2,684,074 shares outstanding.
            What happened to Lixte Biotechnology Holdings’s price movement after its last earnings report?
            Lixte Biotechnology Holdings reported an EPS of -$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Lixte Biotechnology Holdings?
              Currently, no hedge funds are holding shares in LIXT
              ---

              Company Description

              Lixte Biotechnology Holdings

              Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              NovaBay Pharma
              Theriva Biologics
              Titan Pharmaceuticals
              RedHill Biopharma
              Synaptogenix
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis